Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Washington University extends research of Hoth's HT-ALZ in mouse model of Alzheimer's disease

June 10, 2022

New in vitro data support advancing SLS-004 for dementia with Lewy bodies

June 10, 2022

Lundbeck divulges catecholamine prodrugs for Parkinson's disease

June 10, 2022

Find Therapeutics and SATT Conectus sign licensing agreement for new approach to treat MS

June 8, 2022

Korean research groups patent novel antioxidants

June 8, 2022

Biogen and Alectos enter license and collaboration agreement for GBA2 inhibitor for Parkinson's

June 8, 2022

Karolinska Development invests in PharmNovo to advance neuropathic pain treatment

June 7, 2022

Analysis of pain insensitivity disorder reveals new target for pain relief

June 7, 2022

Tau-targeting therapy reduces epilepsy and autism behaviors in model of Dravet syndrome

June 3, 2022

Kavli Neuroscience Prize honors four for genetic discoveries

June 2, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...